[Pharmacotherapies for type 1 diabetes mellitus].
Maruyama
Taro
T
Department of Internal Medicine, Saitama Social Insurance Hospital.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001645:Biguanides / Q000627:therapeutic use; D018834:Chaperonin 60; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000473:pathology / Q000503:physiopathology; D009536:Niacinamide / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D012038:Regeneration; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001645:Biguanides; D018834:Chaperonin 60; C447781:DiaPep 277; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; C460599:NBI6024; D010446:Peptide Fragments; D010455:Peptides; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D009536:Niacinamide